FDA approval positions Lipfendra as blockbuster
Merck's newly approved cholesterol pill Lipfendra is projected to reach over $5 billion in peak annual sales following strong efficacy data.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.